-
公开(公告)号:US20220023407A1
公开(公告)日:2022-01-27
申请号:US17494235
申请日:2021-10-05
申请人: Wyeth LLC
发明人: George Rainer Siber , Peter R. Paradiso , Jill Hackell , Stephen Paul Lockhart , William P. Hausdorff
IPC分类号: A61K39/09 , A61K39/385 , A61K39/02
摘要: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.
-
公开(公告)号:USRE48863E1
公开(公告)日:2021-12-28
申请号:US16388011
申请日:2019-04-18
申请人: WYETH LLC
发明人: Annaliesa Sybil Anderson , Maninder K. Sidhu , Robert G. K. Donald , Kathrin Ute Jansen , Narender K. Kalyan , Justin Keith Moran , Mark E. Ruppen , Michael James Flint
摘要: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号:USRE48862E1
公开(公告)日:2021-12-28
申请号:US16387999
申请日:2019-04-18
申请人: WYETH LLC
发明人: Maninder K. Sidhu , Annaliesa Sybil Anderson , Robert G. K. Donald , Kathrin Ute Jansen , Narender K. Kalyan , Justin Keith Moran , Mark E. Ruppen , Michael James Flint
摘要: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
公开(公告)号:US20200093914A1
公开(公告)日:2020-03-26
申请号:US16598661
申请日:2019-10-10
申请人: Wyeth LLC
发明人: Annaliesa Sybil Anderson , Kathrin Ute Jansen , Mark Edward Ruppen , Justin Keith Moran , Susan Kay Hoiseth
IPC分类号: A61K39/095 , C07K14/22
摘要: The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide, from serogroup B Neisseria meningitides, and methods related thereto.
-
公开(公告)号:US20190388537A1
公开(公告)日:2019-12-26
申请号:US16528680
申请日:2019-08-01
申请人: Wyeth LLC
IPC分类号: A61K39/385 , A61K47/64 , A61K39/09 , A61K39/39
摘要: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
-
公开(公告)号:US20190117645A1
公开(公告)日:2019-04-25
申请号:US16219159
申请日:2018-12-13
申请人: Wyeth, LLC
发明人: Syed M. Shah , Christopher Richard Diorio , Eric C. Ehrnsperger , Xu Meng , Kadum A. Al Shareffi , Jonathan Marc Cohen
IPC分类号: A61K31/485 , A61K9/20 , C07D489/08 , A61K47/20 , A61K47/12 , A61K9/28 , A61K9/00
CPC分类号: A61K31/485 , A61K9/0053 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/28 , A61K47/12 , A61K47/20 , C07D489/08
摘要: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
-
公开(公告)号:US20180265578A1
公开(公告)日:2018-09-20
申请号:US15844526
申请日:2017-12-16
申请人: Wyeth LLC
发明人: Edward Roland LaVallie , Lisa Anne Collins-Racie , Christopher John Corcoran , Lioudmila Gennadievna Tchistiakova , John Adam Nowak , Riyez Karim , Xiang-Yang Tan , Kimberly Ann Marquette , Geertruida Machteld Veldman
IPC分类号: C07K16/22 , A61K39/395 , A61K39/00
CPC分类号: C07K16/22 , A61K39/395 , A61K2039/505 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94 , H05K999/00
摘要: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.
-
公开(公告)号:US09981045B2
公开(公告)日:2018-05-29
申请号:US14695582
申请日:2015-04-24
申请人: Wyeth LLC
发明人: A. Krishna Prasad
IPC分类号: A61K39/385 , A61K47/48 , A61K39/09 , A61K39/00
CPC分类号: A61K47/646 , A61K39/092 , A61K2039/55505 , A61K2039/6037 , A61K2039/70
摘要: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.
-
公开(公告)号:US09902771B2
公开(公告)日:2018-02-27
申请号:US14971536
申请日:2015-12-16
申请人: WYETH LLC
发明人: Erwin R. Boghaert , Nitin K. Damle , Philip Ross Hamann , Kiran Khandke , Arthur Kunz , Kimberly A. Marquette , Lioudmila Tchistiakova , Davinder Gill , Sreekumar R. Kodangattil
CPC分类号: C07K16/28 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K14/82 , C07K16/30 , C07K16/32 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/77 , C07K2317/92
摘要: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
-
公开(公告)号:US20170313749A1
公开(公告)日:2017-11-02
申请号:US15648092
申请日:2017-07-12
申请人: Wyeth LLC
发明人: Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Maninder K. Sidhu , Narender K. Kaylan , Justin Keith Moran , Mark E. Ruppen , Michael James Flint
摘要: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
-
-
-
-
-
-
-
-
-